GlassScriptPhysician profile
Francisco Barrera
NPI 1902854466
$5,980.21
in general payments reported to CMS, 2019-2025
36 companies · $32.04 in 2025
The $32.04 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,549 · 2020: $1,470 · 2021: $1,031 · 2022: $1,557 · 2023: $189 · 2024: $152 · 2025: $32.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $372.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,149.29 | 2019-2022 | |
| Amgen INC. | $562.42 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $541.06 | 2019-2023 | Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $524.98 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $518.85 | 2019-2023 | Synjardy, Jardiance |
| Abbvie INC. | $450.34 | 2019-2022 | |
| Lilly USA, LLC | $408.03 | 2019-2022 | |
| Novo Nordisk INC | $296.92 | 2019-2023 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $190.02 | 2019-2022 | |
| Mannkind Corporation | $171.96 | 2019-2022 | |
| Recordati_rare_diseases_inc. | $150.38 | 2022-2025 | Isturisa, Signifor Lar |
| Cequr Corporation | $145.16 | 2022-2024 | Cequr Simplicity |
| Nevro Corp. | $108.88 | 2020 | |
| Sanofi-Aventis U.S. LLC | $100.65 | 2019-2022 | |
| Astellas Pharma US INC | $99.00 | 2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $81.46 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.78 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $60.11 | 2022 | |
| Allergan, INC. | $46.25 | 2019-2020 | |
| Abbott Laboratories | $32.66 | 2021-2022 | |
| Hologic Sales and Service, LLC | $25.29 | 2020 | |
| Xeris Pharmaceuticals, INC. | $24.69 | 2023 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $20.96 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.48 | 2021 | |
| Genentech USA, INC. | $20.28 | 2020 | |
| Eusa Pharma (US) LLC | $18.47 | 2022 | |
| Glaxosmithkline, LLC. | $18.41 | 2021 | |
| Sequel Med Tech, LLC | $17.80 | 2025 | Twiist |
| Horizon Therapeutics Plc | $14.72 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.56 | 2022 | |
| Evoke Pharma, INC. | $14.30 | 2020 | |
| Exact Sciences Corporation | $13.86 | 2023 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $12.89 | 2020 | |
| Idorsia Pharmaceuticals US INC | $12.89 | 2022 | |
| Circassia INC. | $12.31 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francisco Barrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.